2Savelieva I, Camm AJ. Clinical trends in atrial fibrillation at the turn of the millenium[J]. J Intern Med,2001,250(5) ,369-372.
3Wolf PA, Abbott RD, KannelWB, et al. Atrial fibrillation as an independent risk factor for stroke. The Framingham Study[J]. Stroke, 1991,22(8) : 983-988.
4Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a maior contributor to stroke in the elderly. The Framingham Study[J].Arch Intern Med, 1987,147(9) : 1561-1564.
5Kannel WB, Wolf PA, Benjamin EJ, etal. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates[J]. Am J Cardiol, 1998,82 (SA) : 2N-9N.
6Lip GY, Frison L, Grind M, etal. Effect of hypertension on anti- coagulated patients with atrial fibrillation[J]. Eur Heart J, 2007,28 (6) :752-759.
7AF Investigators. Risk factors for stroke and efficacy of an- tithrombotic therapy in atrial fibrillation[J].Arch Intern Med, 1994,154(13) : 1449-1457.
8Boos CJ, Lip GY. Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology to elinieal trials [J]. J Hum Hypertens,2005,19(11) :855-859.
9Healey JS, Baranchuk A, Crystal E, etal. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and anglotensin receptor blockers: a meta-analysis[J]. J Am Coll Cardiol 2005,45 (11) 1832-1839.
10Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation:a prospective and randomized study[J]. Circulation, 2002,106(3) : 331-336.
